TRI-611 degraded resistant ALK fusion proteins in preclinical models
A compound called TRI-611 routed the target protein into cellular degradation machinery in lung cancer cells carrying ALK fusions, fused forms of the ALK kinase. In the Nature study, it crossed into the brain, reduced wild-type and resistant ALK forms, and produced regression in subcutaneous and intracranial tumour models. The results come from cell lines and patient-derived preclinical models, not evidence of safety or treatment benefit in people.
Science··Morning
The compound routed ALK protein into cellular degradation
TRI-611 was developed as a protein degrader. It positions CRBN, the adaptor used by the CRL4 complex, beside the kinase domain of ALK. The two bind through a surface that is separate from the kinase's active site. This mechanism routed ALK fusion proteins into the cell’s own degradation system and reduced both wild-type forms and variants carrying resistance to approved targeted drugs. The study therefore targets resistant protein away from the active site.[1]
Tumours regressed in subcutaneous and intracranial models
The compound produced tumour regression in models where cell-line and patient-derived tumours were implanted under the skin or inside the skull. The Nature paper reports that TRI-611 crossed into the brain and reduced ALK fusion proteins in intracranial models. Its effect strengthened when combined with conventional ALK inhibitors. These are controlled preclinical experiments, not a response rate measured in patients.[1]
No human trial has yet tested the compound
Every efficacy result in the study is limited to laboratory systems and animal tumour models. These experiments cannot establish what dose can be reached in people, unintended protein effects, safety or treatment benefit. Some non-small-cell lung tumours carry ALK fusions and develop resistance to approved drugs; TRI-611 remains a preclinical candidate for that problem rather than a treatment option.[1]
